They also designed a competitive inhibitor of PD-L1 palmitoylation according to the amino acid sequences near the Cys272 site, which specifically inhibits PD-L1 palmitoylation, reduces PD-L1 expression in cancer cells and enhances the anti-tumor immune responses mediated by T cells [274]. Here, CD274 is linked to neoplasm.